Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 5Uterine Neoplasms 2Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neoplasms, Unknown Primary 2Lung Neoplasms 2Carcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Penile Neoplasms 1Pathologic Complete Response 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Female 1Genital Diseases, Female 1First-line Advanced NSCLC Patients 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Endocrine System Diseases 1Carcinoma, Ovarian Epithelial 1

Interventions

Ocoxin 2niraparib 1anlotinib 1Thalidomide 1Sunitinib 1Spironolactone 1Paclitaxel 1Melphalan 1Leuprolide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1CP protocol 1Bortezomib 1Bevacizumab 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endocrine System Diseases × CP protocol × Clear all
NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Active not recruiting
56 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡